Bronchoscopy-guided antimicrobial therapy for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Jain, Kamini ^a   Wainwright, Claire ^b   Smyth, Alan R ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADVERSE EVENT; ANTIMICROBIAL THERAPY; BACTERIAL CLEARANCE; BACTERIUM ISOLATE; BODY MASS; BRONCHOSCOPY; COUGHING; CYSTIC FIBROSIS; DETERIORATION; DISEASE EXACERBATION; ERADICATION THERAPY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; LUNG FUNCTION; LUNG INFECTION; LUNG LAVAGE; NEWBORN SCREENING; NONHUMAN; NUTRITIONAL PARAMETERS; ONSET AGE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SPUTUM CULTURE; SYSTEMATIC REVIEW; THROAT CULTURE; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; PRESCHOOL CHILD; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE; BRONCHOSCOPY; CHILD, PRESCHOOL; CYSTIC FIBROSIS; HUMANS; INFANT; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897368222     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009530.pub2     Document Type: Review

References (70)

1. Cheney J, Vidmar S, Grimwood K, Carlin JB, Wainwright C, on behalf of ACFBAL Study Group. Interim outcomes of a Pseudomonas aeruginosa (Pa) eradication protocol in young children in the Australian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study [abstract]. Journal of Cystic Fibrosis 2009;8(Suppl 2):S39, Abstract no:157. [CFGD Register: PE167c]
2. Cheney J, Wainwright C, ACFBAL SG. Trials, tribulations and triumphs of a cystic fibrosis study - a behind the scenes look at the workings of an international multi-centre study [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S118, Abstract no: 452. [CFGD Register: PE167g; CRS-ID: 5500125000000092]
3. Wainwright C, Carlin J, Cooper P, Byrnes C, Martin J, Grimwood K, et al.Australasian cystic fibrosis BAL study interim analysis [abstract]. Pediatric Pulmonology 2006;41 Suppl 29:317. [CFGD Register: PE167a]
4. Wainwright CE, Carlin J, Cooper P, Byrnes C, Whitehead B, Martin J, et al.Early infection with pseudomonas aeruginosa can be cleared in young children with cystic fibrosis [abstract]. Pediatric Pulmonology 2002;34 Suppl 24:300-1. [CFGD Register: PI170]
5. Wainwright CE, Kidd TJ, Ramsey KA, Bell SC, Grimwood K. Australasian CF bronchoalveolar lavage (ACFBAL) study: P.Aeruginosa (PA) genotypes in pre-school CF children [abstract]. Pediatric Pulmonology 2011;46 Suppl 34:320, Abstract no: 299. [CFGD Register: PE167h; CRS-ID: 5500125000000093]
6. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, et al.Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011;306(2):163-71.
7. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, et al.Online Supplement to 'Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial' [online]. JAMA 2011;306(2):163-171 Online. [CFGD Register: PE167f; CRS-ID: 5500100000011126]
8. Wainwright CE, Grimwood K, Carlin JB, Vidmar S, Cooper PJ, Francis PW, et al.Safety of bronchoalveolar lavage in young children with cystic fibrosis. Pediatric Pulmonology 2008;43(10):965-72.
9. Chmiel JF, Konstan MW, Lymp J, Mayer-Hamblett N, Hilliard KA, Accurso FJ, et al.Assessment of induced sputum as a tool to evaluate anti-inflammatory agents in CF [abstract]. Pediatric Pulmonology 2007;42 Suppl 30:228. [CFGD Register: PI218]
10. Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 2001;56(4):306-11.
11. Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis [abstract]. Pediatric Pulmonology 1999;28 Suppl 19:312-3. [CFGD Register: PI225]
12. Jyothish D, Desai M, Clarke JR, Weller PH, Gray J. Comparison of Cough Plates with Cough Swabs for identifying lower respiratory tract pathogens in children with Cystic Fibrosis [abstract]. American Thoracic Society International Conference; 2005 May 20-25; San Diego, USA. 2005:C16. [CFGD Register: PI192a]
13. Jyothish D, Desai M, Clarke JR, Weller PH, Gray J. Use of cough plates for identifying lower respiratory tract pathogens in children with cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2005;4 Suppl:S40. [CFGD Register: PI192b]
14. Maiya S, Desai M, Baruah A, Clarke J, Weller P, Gray J. Cough plate versus cough swab [abstract]. Journal of Cystic Fibrosis 2002;1 Suppl 1:S122. [CFGD Register: PI168a]
15. Maiya S, Desai M, Baruah A, Weller P, Clarke JR, Gray J. Cough plate versus cough swab in patients with cystic fibrosis; a pilot study. Archives of Disease in Childhood 2004;89(6):577-9. [CFGD Register: PI168b]
16. McGarvey LPA, Dunbar K, Martin SL, Brown V, MacMahon J, Ennis M, et al.Cytokine concentrations and neutrophil elastase activity in bronchoalveolar lavage and induced sputum from patients with cystic fibrosis, mild asthma and healthy volunteers. Journal of Cystic Fibrosis 2002; Vol. 1, issue 4:269-75. [CFGD Register: PI217]
17. Griese M, Essl R, Schmidt R, Ballmann M, Paul K, Rietschel E, et al.Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. Respiratory Research 2005;6:133. [CFGD Register: IB21i]
18. Jung A, Shute JK, Chen CIU, Ballmann M, Griese M, Ratjen F, et al.Influence of long-term inhaled rhDNase on free and total IL-8 concentration in BAL fluid in cystic fibrosis [abstract]. 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3285. [CFGD Register: IB21d]
19. Paul K, Ballmann M, Griese M, Rietschel E, Chen C, Schink T, et al.Effect of rhDNase on endobronchial inflammation in CF patients with mild lung disease: Results of the multi-center BEAT study [abstract]. Pediatric Pulmonology 2002;34 Suppl 24:310-1. [CFGD Register: IB21c]
20. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, et al.Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2004;169(6):719-25. [CFGD Register: IB21f]
21. Paul KP, Ballmann M, Döring G, Griese M, Kleinau I, Ratjen F, et al.Airway inflammation in CF patients with good pulmonary function - baseline data from the multicenter "BEAT" study [abstract]. Pediatric Pulmonology 1998;26 Suppl 17:383-4. [CFGD Register: IB21a]
22. Paul KP, Rietschel E, Ballmann M, Griese M, Chen CI, Schink T, et al.Longitudinal evaluation of airway inflammation in stable cystic fibrosis (CF) patients by bronchoalveolar lavage (BAL) and influence of rhDNase [abstract]. Proceedings of ATS 99th International Conference, May 16-21, Seattle, USA. 2003:D041 [Poster: E42]. [CFGD Register: IB21e]
23. Ratjen F, Griese M, Ballmann M, Rietschel E, Paul K, Beat Study Group. Dornase alpha in pediatric CF patients with normal lung function - effects on airway inflammation [abstract]. Pediatric Pulmonology 2005;40 Suppl 28:143. [CFGD Register: IB21h]
24. Ratjen F, Paul K, Rietschel E, Nikolaizik W. Treatment with rhDNase reduces DNA levels in BAL fluid of CF patients with mild lung disease [abstract]. Pediatric Pulmonology 2002;34 Suppl 24:310. [CFGD Register: IB21b]
25. Ratjen F, Paul K, van Koningsbruggen S, Breitenstein S, Rietschel E, Nikolaizik W. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: Influence of treatment with dornase alpha. Pediatric Pulmonology 2005;39(1):1-4. [CFGD Register: IB21g]
26. Rosenfeld M, Emerson J, Uh D, Anderson G, Genatossio A, McNamara S, et al.Does tobramycin accumulate in respiratory secretions with repeated aerosol administration: a pilot study [abstract]. Pediatric Pulmonology 2006;41 Suppl 29:327. [CFGD Register: PI203]
27. Taylor L, Corey M, Matlow A, Geremia J, Sweezey N. Nasopharyngeal auger suction vs throat swab cultures in CF patients [abstract]. Pediatric Pulmonology 1998;26 Suppl 17:399. [CFGD Register: PI147a]
28. Taylor L, Corey M, Matlow A, Sweezey NB, Ratjen F. Comparison of throat swabs and nasopharyngeal suction specimens in non-sputum-producing patients with cystic fibrosis. Pediatric Pulmonology 2006;41(9):839-43. [CFGD Register: PI147b]
29. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310(6994):1571-2.
30. Aurora P, Bush A, Gustafsson P, Oliver C, Wallis C, Price J, et al.Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2005;171(3):249-56.
31. Baughman RP, Keeton DA, Perez C, Wilmott RW. Use of bronchoalveolar lavage semi-quantitative cultures in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1997;156(1):286-91.
32. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Human Mutation 2002;19(6):575-606.
33. Brody AS, Klein JS, Molina PL, Quan J, Bean JA, Wilmott RW. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. Journal of Pediatrics 2004;145(1):32-8.
34. Dankert-Roelse JE, Merelle ME. Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. Journal of Pediatrics 2009;147(3 Suppl):S15-20.
35. de Blic J, Marchac V, Scheinmann P. Complications of flexible bronchoscopy in children: prospective study of 1, 328 procedures. European Respiratory Journal 2002;20(5):1271-6.
36. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
37. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. European Respiratory Journal 2007;29(3):522-6.
38. Farrell PM, Kosorok MR, Laxova A, Shen G, Koscik RE, Bruns WT, et al.Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. New England Journal of Medicine 1997;337(14):963-9.
39. Farrell PM, Shen G, Splaingard M, Colby CE, Laxova A, Kosorok MR, et al.Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 1997;100(5):E2. [DOI: 10.1542/peds.100.5.e2]
40. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatric Pulmonology 1997;23(5):330-5.
41. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54.
42. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Criticial Care Medicine 2003;168(8):918-51.
43. Gilchrist FJ, Salamat S, Clayton S, Peach J, Alexander J, Lenney W. Bronchoalveolar lavage in children with cystic fibrosis: how many lobes should be sampled?. Archives of Disease in Childhood 2011;96(3):215-7.
44. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. Journal of Cystic Fibrosis 2008;7(6):523-30.
45. Heim RA, Sugarman EA, Allitto BA. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel. Genetics in Medicine: Official Journal of the American College of Medical Genetics 2001;3(3):168-76.
46. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
47. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
48. Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
49. Hilliard TN, Sukhani S, Francis J, Madden N, Rosenthal M, Balfour-Lynn I, et al.Bronchoscopy following diagnosis with cystic fibrosis. Archives of Disease in Childhood 2007;92(10):898-9.
50. Ikeda S, Yani N, Ishikawa S. Flexible bronchofiberscope. Keio Journal of Medicine 1968;17(1):1-16.
51. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1995;151(4):1075-82.
52. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD004197.pub3]
53. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis 2003;2(1):29-34.
54. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al.Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293(5):581-8.
55. Loeve M, van Hal PT, Robinson P, de Jong PA, Lequin MH, Hop WC, et al.The spectrum of structural abnormalities on CT scans from patients with CF with severe advanced lung disease. Thorax 2009;64(10):876-82.
56. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Journal of Clinical Epidemiology 2009;62(10):1006-12.
57. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, et al.Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Pediatrics 2001;138(5):699-704.
58. Nussbaum E. Pediatric fiberoptic bronchoscopy: Clinical experience with 2, 836 bronchoscopies. Pediatric Critical Care Medicine 2002;3(2):171-6.
59. Picard E, Schwartz S, Goldberg S, Glick T, Villa Y, Kerem E. A prospective study of fever and bacteremia after flexible fiberoptic bronchoscopy in children. Chest 2000;117(2):573-7.
60. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
61. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, et al.Pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology 2004;37(5):400-6.
62. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, et al.Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatric Pulmonology 1999;28(5):321-8.
63. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, et al.Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 2001;139(3):359-65.
64. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. Journal of Pediatrics 1998;132(4):589-95.
65. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, et al.Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. American Journal of Respiratory and Critical Care Medicine 2009;180(2):146-52.
66. Southern KW, Merelle Marieke ME, Dankert-Roelse JE, Nagelkerke AD. Newborn screening for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD001402.pub2]
67. Stafler P, Davies J C, Balfour-Lynn I M, Rosenthal M, Bush A. Bronchoscopy in cystic fibrosis infants diagnosed by newborn screening. Pediatric Pulmonology 2011;46(7):696-700.
68. Stuart B, Lin J H, Mogayzel P J Jr. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatric Respiratory Reviews 2010;11(3):177-84.
69. UK CF Trust. Pseudomonas aeruginosa infection in people with cystic fibrosis. Report of UK CF Trust Infection Control group 2004.
70. Wood RE, Fink RJ. Applications of flexible fiberoptic bronchoscopes in infants and children. Chest 1978;73(5 Suppl):737-40.